Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.55 |
| ▸ | ITGAV | P06756 | 6/20 | 0.55 |
| ▸ | MC4R | P32245 | 6/20 | 0.50 |
| ▸ | MC5R | P33032 | 6/20 | 0.50 |
| ▸ | MC3R | P41968 | 6/20 | 0.50 |
| ▸ | MC1R | Q01726 | 6/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.49 |
| ▸ | CTSG | P08311 | 2/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22003475 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL10052602 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL16298655 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL26200853 | 0.96 | ITGB3 (0.55) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL14115074 | 0.96 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL19725710 | 0.95 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL15188715 | 0.95 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12361592 | 0.95 | MC4R (0.51) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL19725628 | 0.95 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13870347 | 0.94 | ITGB3 (0.63) | ITGB3ITGAVMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723991-B2 | Radiopharmaceutical compositions | SERAC HEALTHCARE LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20210060189-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | SERAC HEALTHCARE LIMITED (GB) | 2021-03-04 | — | — | US | disclosed |
| US-9987382-B2 | Radiotracer compositions | GE HEALTHCARE LIMITED (GB) | 2018-06-05 | — | — | US | disclosed |
| US-20160022847-A1 | Radiotracer Compositions | GE HEALTHCARE LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-7875701-B2 | A radiopharmaceutical based on a clyclic oligopeptide containing a fluorine isotope and the triplet amino acid sequence of arginine-glycine-aspartic acid (RGD); angiogenesis inhibitors by binding to integrin receptors; imaging using tomography; anticariogenic , -tumor and - arthritic agents; cardiotonic | GE HEALTHCARE AS (NO) | 2011-01-25 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20080095701-A1 | Diagnostic Compounds | SOLBAKKEN MAGNE | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022847-A1 | Radiotracer Compositions | FOLR2, FOLR1, PAICS | ITGB3 1138/4885ITGAV 1221/4885MC4R 2453/4885 |
| US-20080095701-A1 | Diagnostic Compounds | CA13, SLCO1B3, KLK3 | ITGB3 111/4885ITGAV 481/4885MC4R 1747/4885 |
| US-11723991-B2 | Radiopharmaceutical compositions | TYMP, KIT, CHEK1 | ITGB3 2816/4885ITGAV 3650/4885MC4R 576/4885 |
| US-20210060189-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | TYMP, KIT, CHEK1 | ITGB3 2816/4885ITGAV 3650/4885MC4R 576/4885 |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | ITGB3 917/4885ITGAV 180/4885MC4R 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.